Showing 1171-1180 of 1347 results for "".
- Measuring Levels of Proteins in Eye Fluid May Accurately Predict Need for Lifelong Macular Degeneration Therapyhttps://modernod.com/news/measuring-levels-of-proteins-in-eye-fluid-may-accurately-predict-need-for-lifelong-macular-degeneration-therapy/2480947/In a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration (AMD) may need lifelong, frequent eye injections to preserve v
- Recipients of the 2022 Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award Announcedhttps://modernod.com/news/recipients-of-the-2022-prevent-blindness-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award-announced/2480762/Prevent Blindness has announced the recipient of the 2022 Jenny Pomeroy Award for Excellence in Vision and Public Health as VOSH/International (V/I). Additionally, Prevent Blindness has announced the co-recipients of the third annual “Rising Visionary Award” as Marissa K. Sh
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtualhttps://modernod.com/news/new-data-for-thyroid-eye-disease-treatment-tepezza-to-be-presented-at-aao-virtual/2478527/Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data will be presented at the American Academy of Ophthalmology Annual Meeting, Nov. 13-15, 2020. Tepezza is the first and only medicine approved by the FDA for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and v
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Modernizing Medicine Launches Telehealth-Enabled EHR to Reduce Risk of COVID-19 Transmissionhttps://modernod.com/news/modernizing-medicine-launches-telehealth-enabled-ehr/2477466/Modernizing Medicine launched its audio and video telemedicine product to swiftly serve current and future clients and the health care community. The company said it recognizes the importance of remotely evaluating patients to help reduce the risk of COVID-19 transmission and to provide care to v
- James Mazzo Joins Board of Directors at Avellino Labshttps://modernod.com/news/james-mazzo-joins-board-of-directors-at-avellino-labs/2476451/Avellino Labs announced the strategic addition of James V. Mazzo to its board of directors. The partnership will further anchor Avellino Lab’s leadership in developing the science and setting the standard of genetic testing in ophthalmology, according to a company news release.
- First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI Surgical System for MIGS Procedureshttps://modernod.com/news/first-subjects-enrolled-in-clinical-study-to-evaluate-safety-and-efficacy-of-omni-surgical-system-for-migs-procedures/2476422/Sight Sciences announced that enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multicenter study to evaluate the safety and efficacy of the OMNI Surgical System in performing two sequential micro-invasive glaucoma surgery (MIGS) procedures—transluminal v